Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease

SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced. Unlike many current therapies, the mechanism of action of SGLT2 inhibitors is independent of ins...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanoli, L., Granata, A., Lentini, P., Rastelli, S., Fatuzzo, P., Rapisarda, F., Castellino, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345065/
https://www.ncbi.nlm.nih.gov/pubmed/25785281
http://dx.doi.org/10.1155/2015/317507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345065/
https://www.ncbi.nlm.nih.gov/pubmed/25785281
http://dx.doi.org/10.1155/2015/317507

Ejemplares similares